GRFS - Grifols sees revenue contribution from new product launches to ramp by 2030

Grifols ([[GRFS]] -4.2%) forecasts new product sales to make up about one fifth of the company's total revenue by 2030.The company, in its investor presentation slides as part of its analyst day, forecast revenue from new product launches to grow to 20% of its total topline by 2030, up from about 4% in 2020.The company also highlighted that it intends to focus on therapeutic areas, and expects to progressively incorporate non-plasma assets to balance its portfolio.The company's shares have lost nearly 5% of their value YTD.Seeking Alpha contributor Stanislas Capital recently opined that the plasma-supply disruption provides an attractive entry point for the company, and highlighted that Grifols operates in the very attractive and lucrative plasma business.Grifols started commercializing HyperHEP B, a new formulation of its hepatitis B immune globulin for hepatitis B postexposure prophylaxis, earlier this week.

For further details see:

Grifols sees revenue contribution from new product launches to ramp by 2030